Definium Therapeutics (NASDAQ:DFTX) Stock Price Up 5.3% – What’s Next?

Definium Therapeutics, Inc. (NASDAQ:DFTX) shares were up 5.3% on Monday. The company traded as high as $38.38 and last traded at $38.08. Approximately 1,262,536 shares traded hands during trading, a decline of 44% from the average session volume of 2,263,909 shares. The stock had previously closed at $36.17.

Key Headlines Impacting Definium Therapeutics

Here are the key news stories impacting Definium Therapeutics this week:

• Positive Sentiment: Analysts remain broadly constructive on Definium’s pipeline of psychiatric and neurological therapies. The stock has a consensus “Buy” rating and an average price target of $64.88, well above its recent trading level. JonesTrading also raised its target to $90, while UBS, Oppenheimer and HC Wainwright maintained bullish ratings. Definium Therapeutics analyst coverage
• Positive Sentiment: Definium awarded options covering 334,810 shares to 15 newly hired non-executive employees. The grants may help the late-stage biotechnology company attract talent needed to advance its clinical programs, including MM120 and DT402. Definium Therapeutics Announces New Employee Inducement Grants
• Neutral Sentiment: The employee option awards also create potential future share dilution. No new clinical-trial results, regulatory milestones or changes to the company’s operating outlook were reported in these updates.
• Negative Sentiment: Four insiders sold a combined 52,075 shares for approximately $1.90 million at an average price of $36.57. The sales included CEO Robert Barrow’s 31,550 shares, Mark Sullivan’s 14,051 shares, CFO Brandi Roberts’ 3,377 shares and Matthew Wiley’s 3,097 shares. Each insider retained a sizable position, but the coordinated selling can raise near-term concerns about insider confidence. Definium Therapeutics insider trading report

Wall Street Analysts Forecast Growth

DFTX has been the topic of several research reports. Stifel Nicolaus upped their price target on shares of Definium Therapeutics from $30.00 to $60.00 and gave the company a “buy” rating in a research note on Wednesday, July 8th. Maxim Group set a $55.00 price objective on shares of Definium Therapeutics and gave the stock a “buy” rating in a research note on Friday, August 14th. UBS Group reissued a “buy” rating and issued a $70.00 price objective on shares of Definium Therapeutics in a report on Tuesday, September 15th. Wells Fargo & Company increased their target price on shares of Definium Therapeutics from $68.00 to $72.00 and gave the stock an “overweight” rating in a research report on Thursday, August 13th. Finally, Robert W. Baird raised their target price on shares of Definium Therapeutics from $75.00 to $79.00 and gave the stock an “outperform” rating in a report on Tuesday, September 15th. Two analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Definium Therapeutics presently has an average rating of “Buy” and an average target price of $64.88.

Definium Therapeutics Trading Down 0.5%

The stock has a market capitalization of $5.13 billion, a P/E ratio of -11.14 and a beta of 2.23. The company has a current ratio of 6.95, a quick ratio of 6.95 and a debt-to-equity ratio of 0.04. The business has a 50-day moving average price of $41.37 and a two-hundred day moving average price of $32.06.

Definium Therapeutics (NASDAQ:DFTX) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($1.44) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.89). On average, analysts expect that Definium Therapeutics, Inc. will post -3.02 EPS for the current fiscal year.

Insider Activity

In other Definium Therapeutics news, insider Mark Sullivan sold 14,051 shares of the firm’s stock in a transaction dated Friday, September 25th. The shares were sold at an average price of $36.57, for a total value of $513,845.07. Following the transaction, the insider directly owned 494,228 shares of the company’s stock, valued at $18,073,917.96. This trade represents a 2.76% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Robert Barrow sold 31,550 shares of the firm’s stock in a transaction dated Friday, September 25th. The shares were sold at an average price of $36.57, for a total transaction of $1,153,783.50. Following the completion of the transaction, the chief executive officer directly owned 2,213,090 shares in the company, valued at approximately $80,932,701.30. This represents a 1.41% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 71,098 shares of company stock valued at $2,626,115. Corporate insiders own 2.40% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in DFTX. Nykredit A S acquired a new stake in Definium Therapeutics during the 2nd quarter worth approximately $45,000. Allworth Financial LP bought a new stake in Definium Therapeutics during the second quarter valued at $110,000. Integrated Wealth Concepts LLC acquired a new stake in Definium Therapeutics during the second quarter worth approximately $159,000. NewEdge Advisors LLC bought a new stake in shares of Definium Therapeutics in the 2nd quarter valued at $222,000. Finally, WINTON GROUP Ltd acquired a new position in shares of Definium Therapeutics during the second quarter valued at about $240,000. 27.91% of the stock is currently owned by institutional investors and hedge funds.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.